Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer

Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/6 inhibitors has significantly improved progression-free su...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2018-06, Vol.11 (1), p.80-80, Article 80
Main Authors: D'Souza, Anishka, Spicer, Darcy, Lu, Janice
Format: Article
Language:English
Subjects:
Breast cancer
Care and treatment
Cell cycle
Cell division
Complications and side effects
Cyclin-dependent kinase 4
Development and progression
Dosage and administration
Drug therapy
Endocrine therapy
Genetic aspects
Hematology
Kinases
Metabolism
Metabolites
Metastases
Metastasis
Mutation
Oncology
Phosphorylation
Quality of life
Review
Tamoxifen
TOR protein
Tumors
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c591t-843d6ce8f83d37b347e046215f1618e17712853209e16eeefbf4e7e0eeae45233
cites cdi_FETCH-LOGICAL-c591t-843d6ce8f83d37b347e046215f1618e17712853209e16eeefbf4e7e0eeae45233
container_end_page 80
container_issue 1
container_start_page 80
container_title Journal of hematology and oncology
container_volume 11
creator D'Souza, Anishka
Spicer, Darcy
Lu, Janice
description Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/6 inhibitors has significantly improved progression-free survival in this group of patients. There are multiple studies of the use of P13K inhibitors and mTOR inhibitors for use as subsequent lines of therapy, particularly for endocrine resistance. The optimal sequencing of therapy should be based on medical comorbidities, prior adjuvant therapies, quality of life, side-effect profile, and disease-free interval.
doi_str_mv 10.1186/s13045-018-0620-6
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_77e961727f2548b9a29cdac6061d55cd</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A546894584</galeid><doaj_id>oai_doaj_org_article_77e961727f2548b9a29cdac6061d55cd</doaj_id><sourcerecordid>A546894584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c591t-843d6ce8f83d37b347e046215f1618e17712853209e16eeefbf4e7e0eeae45233</originalsourceid><addsrcrecordid>eNptks1u1DAURiMEomXgAdigSEiomxTb8e8GqaooVKrUDV1bjnMz41FiD7YzEm-P0yllBqEskjjnnjhfvqp6j9ElxpJ_TrhFlDUIywZxghr-ojrHgvFGCkJeHl2fVW9S2iLEsSLodXVGlFQYIXJePdzvIdowOb-uwffBRuehjpBcysZbqJ2vJ8im3GVn602IU3gELOxyiM0uJJfdHuouQoFquwzFt9WrwYwJ3j2dV9XDzdcf19-bu_tvt9dXd41lCudG0rbnFuQg274VXUsFIMoJZgPmWAIWAhPJWoIUYA4AQzdQKAyAAcpI266q24O3D2ard9FNJv7SwTj9uBDiWptY9j2CFgIUx4KIgTAqO2WIsr2xvGTSM2b74vpycO3mboLegs_RjCfS0yfebfQ67DVTilOOiuDiSRDDzxlS1pNLFsbReAhz0gQxqjBXlBX04z_oNszRl6gWigtJi_EvtTblA5wfQnmvXaT6ilEui6kkuKou_0OVo4fJ2fKzBlfWTwY-HQ1swIx5k8I4Zxd8OgXxAbQxpBRheA4DI70UUB8KqEsB9VJAvez5w3GKzxN_Gtf-Bsmp1Mc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2056784646</pqid></control><display><type>article</type><title>Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><creator>D'Souza, Anishka ; Spicer, Darcy ; Lu, Janice</creator><creatorcontrib>D'Souza, Anishka ; Spicer, Darcy ; Lu, Janice</creatorcontrib><description>Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/6 inhibitors has significantly improved progression-free survival in this group of patients. There are multiple studies of the use of P13K inhibitors and mTOR inhibitors for use as subsequent lines of therapy, particularly for endocrine resistance. The optimal sequencing of therapy should be based on medical comorbidities, prior adjuvant therapies, quality of life, side-effect profile, and disease-free interval.</description><identifier>ISSN: 1756-8722</identifier><identifier>EISSN: 1756-8722</identifier><identifier>DOI: 10.1186/s13045-018-0620-6</identifier><identifier>PMID: 29891002</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Breast cancer ; Care and treatment ; Cell cycle ; Cell division ; Complications and side effects ; Cyclin-dependent kinase 4 ; Development and progression ; Dosage and administration ; Drug therapy ; Endocrine therapy ; Genetic aspects ; Hematology ; Kinases ; Metabolism ; Metabolites ; Metastases ; Metastasis ; Mutation ; Oncology ; Phosphorylation ; Quality of life ; Review ; Tamoxifen ; TOR protein ; Tumors ; Womens health</subject><ispartof>Journal of hematology and oncology, 2018-06, Vol.11 (1), p.80-80, Article 80</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><rights>Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c591t-843d6ce8f83d37b347e046215f1618e17712853209e16eeefbf4e7e0eeae45233</citedby><cites>FETCH-LOGICAL-c591t-843d6ce8f83d37b347e046215f1618e17712853209e16eeefbf4e7e0eeae45233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996460/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2056784646?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29891002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>D'Souza, Anishka</creatorcontrib><creatorcontrib>Spicer, Darcy</creatorcontrib><creatorcontrib>Lu, Janice</creatorcontrib><title>Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer</title><title>Journal of hematology and oncology</title><addtitle>J Hematol Oncol</addtitle><description>Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/6 inhibitors has significantly improved progression-free survival in this group of patients. There are multiple studies of the use of P13K inhibitors and mTOR inhibitors for use as subsequent lines of therapy, particularly for endocrine resistance. The optimal sequencing of therapy should be based on medical comorbidities, prior adjuvant therapies, quality of life, side-effect profile, and disease-free interval.</description><subject>Breast cancer</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Cell division</subject><subject>Complications and side effects</subject><subject>Cyclin-dependent kinase 4</subject><subject>Development and progression</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Endocrine therapy</subject><subject>Genetic aspects</subject><subject>Hematology</subject><subject>Kinases</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Phosphorylation</subject><subject>Quality of life</subject><subject>Review</subject><subject>Tamoxifen</subject><subject>TOR protein</subject><subject>Tumors</subject><subject>Womens health</subject><issn>1756-8722</issn><issn>1756-8722</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks1u1DAURiMEomXgAdigSEiomxTb8e8GqaooVKrUDV1bjnMz41FiD7YzEm-P0yllBqEskjjnnjhfvqp6j9ElxpJ_TrhFlDUIywZxghr-ojrHgvFGCkJeHl2fVW9S2iLEsSLodXVGlFQYIXJePdzvIdowOb-uwffBRuehjpBcysZbqJ2vJ8im3GVn602IU3gELOxyiM0uJJfdHuouQoFquwzFt9WrwYwJ3j2dV9XDzdcf19-bu_tvt9dXd41lCudG0rbnFuQg274VXUsFIMoJZgPmWAIWAhPJWoIUYA4AQzdQKAyAAcpI266q24O3D2ard9FNJv7SwTj9uBDiWptY9j2CFgIUx4KIgTAqO2WIsr2xvGTSM2b74vpycO3mboLegs_RjCfS0yfebfQ67DVTilOOiuDiSRDDzxlS1pNLFsbReAhz0gQxqjBXlBX04z_oNszRl6gWigtJi_EvtTblA5wfQnmvXaT6ilEui6kkuKou_0OVo4fJ2fKzBlfWTwY-HQ1swIx5k8I4Zxd8OgXxAbQxpBRheA4DI70UUB8KqEsB9VJAvez5w3GKzxN_Gtf-Bsmp1Mc</recordid><startdate>20180611</startdate><enddate>20180611</enddate><creator>D'Souza, Anishka</creator><creator>Spicer, Darcy</creator><creator>Lu, Janice</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180611</creationdate><title>Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer</title><author>D'Souza, Anishka ; Spicer, Darcy ; Lu, Janice</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c591t-843d6ce8f83d37b347e046215f1618e17712853209e16eeefbf4e7e0eeae45233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Breast cancer</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Cell division</topic><topic>Complications and side effects</topic><topic>Cyclin-dependent kinase 4</topic><topic>Development and progression</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Endocrine therapy</topic><topic>Genetic aspects</topic><topic>Hematology</topic><topic>Kinases</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Phosphorylation</topic><topic>Quality of life</topic><topic>Review</topic><topic>Tamoxifen</topic><topic>TOR protein</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>D'Souza, Anishka</creatorcontrib><creatorcontrib>Spicer, Darcy</creatorcontrib><creatorcontrib>Lu, Janice</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of hematology and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>D'Souza, Anishka</au><au>Spicer, Darcy</au><au>Lu, Janice</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer</atitle><jtitle>Journal of hematology and oncology</jtitle><addtitle>J Hematol Oncol</addtitle><date>2018-06-11</date><risdate>2018</risdate><volume>11</volume><issue>1</issue><spage>80</spage><epage>80</epage><pages>80-80</pages><artnum>80</artnum><issn>1756-8722</issn><eissn>1756-8722</eissn><abstract>Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/6 inhibitors has significantly improved progression-free survival in this group of patients. There are multiple studies of the use of P13K inhibitors and mTOR inhibitors for use as subsequent lines of therapy, particularly for endocrine resistance. The optimal sequencing of therapy should be based on medical comorbidities, prior adjuvant therapies, quality of life, side-effect profile, and disease-free interval.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>29891002</pmid><doi>10.1186/s13045-018-0620-6</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1756-8722
ispartof Journal of hematology and oncology, 2018-06, Vol.11 (1), p.80-80, Article 80
issn 1756-8722
1756-8722
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_77e961727f2548b9a29cdac6061d55cd
source PubMed (Medline); Publicly Available Content Database
subjects Breast cancer
Care and treatment
Cell cycle
Cell division
Complications and side effects
Cyclin-dependent kinase 4
Development and progression
Dosage and administration
Drug therapy
Endocrine therapy
Genetic aspects
Hematology
Kinases
Metabolism
Metabolites
Metastases
Metastasis
Mutation
Oncology
Phosphorylation
Quality of life
Review
Tamoxifen
TOR protein
Tumors
Womens health
title Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A19%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overcoming%20endocrine%20resistance%20in%20metastatic%20hormone%20receptor-positive%20breast%20cancer&rft.jtitle=Journal%20of%20hematology%20and%20oncology&rft.au=D'Souza,%20Anishka&rft.date=2018-06-11&rft.volume=11&rft.issue=1&rft.spage=80&rft.epage=80&rft.pages=80-80&rft.artnum=80&rft.issn=1756-8722&rft.eissn=1756-8722&rft_id=info:doi/10.1186/s13045-018-0620-6&rft_dat=%3Cgale_doaj_%3EA546894584%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c591t-843d6ce8f83d37b347e046215f1618e17712853209e16eeefbf4e7e0eeae45233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2056784646&rft_id=info:pmid/29891002&rft_galeid=A546894584&rfr_iscdi=true